For software as a medical device (SaMD), choose an eQMS, a PLM system, or both by mapping the processes and evidence you must control—not by assuming one acronym is inherently compliant. An eQMS is typically centered on quality-system processes and records; PLM is typically centered on product definition, engineering changes, configuration, and product-data traceability. Their functions can overlap, so the deciding questions are who owns each record, how evidence connects across the lifecycle, and whether you can retrieve a complete, trustworthy history.
What is the practical difference between eQMS and PLM?
An electronic quality management system (eQMS) generally organizes controlled quality processes and records. Product lifecycle management (PLM) generally organizes product and engineering information, including requirements, configurations, and changes. Those are useful starting points, not hard boundaries: vendors describe products that extend into the other system’s territory.
| Area | Typical eQMS focus | Typical PLM focus | What to establish for SaMD |
|---|---|---|---|
| Quality-system processes | Controlled procedures, approvals, training, audits, nonconformances, CAPA, and quality records | Whether quality processes are available and how they connect to product records | Which system controls each quality workflow and retains its authoritative record |
| Requirements and traceability | Links from procedures and quality evidence to engineering records, often through integration | Requirements linked to design, tests, versions, and product configurations | How a requirement can be followed through design and verification/validation evidence |
| Changes and configuration | Quality change review, impact assessment, approvals, and controlled records | Product baselines, software or product configuration, dependencies, and engineering change impact | How a change to software, documentation, or a process affects the approved product and its evidence |
| Risk and verification evidence | Quality risk, CAPA, audit trails, and links to supporting records | Connections among risk, requirements, design outputs, and test evidence | How the evidence set supports the organization’s lifecycle processes without treating a tool as a substitute for them |
| Inspection and record retrieval | Search, permissions, audit trail, retention, and export for QMS records | Product history and connected design and engineering records | Whether authorized staff can retrieve a complete, readable record set across systems |
| Software used in production or the QMS | Assurance for automation used in quality workflows | Assurance for PLM automation used in production or QMS workflows | Intended use, risk, configuration, and assurance evidence for the software’s actual use |
FDA’s SaMD lifecycle material describes processes spanning requirements management, design, development, verification and validation, deployment, maintenance, and decommissioning. That lifecycle is broader than any one application’s feature list. A system should make the applicable work and evidence manageable; it does not perform the manufacturer’s quality responsibilities by itself.
Does FDA require an eQMS or a PLM system?
The cited FDA materials describe quality-system and SaMD lifecycle expectations; they do not establish a required software category or a rule that an eQMS must replace PLM, or vice versa. The regulatory target is the manufacturer’s controlled processes and records, not the product label on the software it buys.
#1 Best Overall
The U.S. QMSR in effect
As of October 4, 2026, FDA’s Quality Management System Regulation (QMSR) has been effective since February 2, 2026. It amends device current good manufacturing practice requirements in 21 CFR Part 820 and incorporates ISO 13485:2016 by reference. FDA says it applies to finished-device manufacturers intending to commercially distribute medical devices. FDA also says QMSR inspections use the updated inspection process; the former QSIT inspection documents are no longer used after the effective date.
Records and software assurance still matter
FDA’s QMSR FAQ says investigators may review QMS records created before the effective date and that management-review, quality-audit, and supplier-audit reports are available for FDA inspection under QMSR. A purchasing decision should therefore address the organization’s record history and retrieval needs, not only future workflows.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
FDA’s February 2026 computer software assurance guidance recommends a risk-based approach to establish confidence in computers and automated data-processing systems used as part of medical-device production or the QMS. It superseded FDA’s September 24, 2025 final guidance. This makes intended use important: evaluate assurance for the functions the software actually performs, including relevant automation, rather than assuming a system is outside scope because it is called PLM or eQMS.
How do SaMD lifecycle standards fit into the comparison?
SaMD lifecycle processes
FDA’s SaMD page describes IMDRF frameworks as harmonized principles and vocabulary, not regulations. The same page says good software quality and engineering practices need to be incorporated into the device’s quality management system. For system selection, translate those lifecycle activities into concrete records and handoffs: requirements, design decisions, verification and validation, releases, maintenance, and decommissioning.
IEC 62304 is not the whole release process
FDA recognizes IEC 62304 for medical-device software lifecycle processes when software is itself a medical device or is embedded in or integral to a finished device. FDA’s recognition record states that the standard covers development and maintenance, but not validation and final release of the device. Do not treat an IEC 62304 workflow in either platform as proof that the complete device validation and release process is covered.
How should you decide whether to use one system or both?
Start with a real workflow rather than a vendor feature checklist. Trace a change from a user need or requirement through design, risk assessment, verification and validation, release approval, and post-release maintenance. Include a quality corrective action if the example warrants one. This exposes where information originates, who approves it, and what must be retrievable together.
Rank #4
- List required processes and records. Include applicable quality workflows as well as product-development and maintenance evidence. Tie each item to your procedures and intended markets rather than assuming a generic feature list is sufficient.
- Assign an authoritative record owner. For every record type, name the system where the controlled version lives, the role accountable for it, and the approval path. If a record is referenced in another system, define which copy is authoritative.
- Map links across the lifecycle. Test how requirements connect to design, risk, tests, releases, and later changes. Confirm that version changes do not silently break traceability or leave evidence tied to the wrong configuration.
- Check retrieval and history. Demonstrate how staff can locate an end-to-end record set, including older records where relevant, with the access controls, audit trail, retention, and export your procedures require.
- Assess the integration boundary. Identify data passed between systems, manual re-entry, duplicate approvals, failure handling, and responsibility for resolving inconsistent records. Specify how the integration itself is controlled.
- Assess software assurance by intended use. For automation used in production or the QMS, document what it does, the risks of its failure, and the assurance evidence appropriate to that use under FDA’s February 2026 guidance.
- Run a representative scenario before deciding. In a demonstration or evaluation environment, execute the full change workflow and retrieve its records as an inspector or internal reviewer would. A polished module list is not evidence that the configured process works for your organization.
If one platform can cover the needed processes and preserve clear ownership and retrieval, a second platform may not be necessary. If specialized quality and engineering workflows are both needed, using both can be practical—but only with explicit system-of-record boundaries and tested evidence flows. FDA’s lifecycle and record expectations, together with the vendors’ overlapping descriptions, support this workflow-based evaluation rather than a universal architecture prescription.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What should you verify in vendor demonstrations?
Examples below are capabilities described by the vendors themselves, not independent compliance findings, product endorsements, or evidence that a particular configuration satisfies a manufacturer’s QMS.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Siemens medical-device PLM
Siemens describes a medical-device PLM offer that includes design-data management, product-line variation, requirements-to-verification/validation mapping, change control, CAPA, and design-history/manufacturing-record traceability. Ask the vendor to show how those functions work together for your product configuration and procedures.
MasterControl eQMS
MasterControl describes an eQMS offering for medical-device quality management. Confirm in a demonstration that the processes and records you need are supported, including training, audit trails, migration, and required integrations.
PTC PLM
PTC describes PLM quality capabilities including change and configuration management, requirements and test management, CAPA, nonconformance, audits, document control, and risk analysis. Validate the scope and configuration directly against your workflows rather than inferring coverage from the product category.
The cited vendor pages do not provide comparative test results, pricing, verified implementation outcomes, or a product recommendation for a particular organization. None of these descriptions means FDA has approved or certified the product.
Quick Recap
What commonly goes wrong?
- Choosing by acronym. A system’s category does not establish that your processes, controls, and records are adequate.
- Keeping competing authoritative records. Duplicate approvals or conflicting versions make it harder to establish what was approved and which evidence supports a release.
- Breaking traceability at integration points. A link that does not carry version or configuration context can connect valid-looking evidence to the wrong product state.
- Assuming a standard feature covers every lifecycle duty. IEC 62304, for example, does not cover device validation and final release in FDA’s recognition record.
- Evaluating only the new system. QMSR inspection can include records created before February 2, 2026, so migration and historical retrieval should be part of planning.
- Treating a vendor claim as proof. A described capability needs to be demonstrated in the proposed configuration and evaluated against your procedures and evidence needs.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
